Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1658
mi
from 43215
Tempe, AZ
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1658
mi
from 43215
Tempe, AZ
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
563
mi
from 43215
Springfield, MA
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
563
mi
from 43215
Springfield, MA
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
405
mi
from 43215
Bethlehem, PA
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
405
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
9459
mi
from 43215
Camperdown,
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
9459
mi
from 43215
Camperdown,
Click here to add this to my saved trials
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
277
mi
from 43215
Springfield, VA
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
277
mi
from 43215
Springfield, VA
Click here to add this to my saved trials
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
11251
mi
from 43215
Nedlands,
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
11251
mi
from 43215
Nedlands,
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
316
mi
from 43215
Fairfax, VA
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
316
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated:  12/31/1969
Research Site
9882
mi
from 43215
Parkville,
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Status: Enrolling
Updated: 12/31/1969
Research Site
9882
mi
from 43215
Parkville,
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2109
mi
from 43215
Greenbrae, CA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2109
mi
from 43215
Greenbrae, CA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2107
mi
from 43215
Santa Rosa, CA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2107
mi
from 43215
Santa Rosa, CA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
188
mi
from 43215
Louisville, KY
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
206
mi
from 43215
Kalamazoo, MI
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
206
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Fractional Urate Excretion in Nonedematous Hyponatremia
Study of Nonedematous Hyponatremia and the Utility of Fractional Urate Excretion in Hyponatremia and Suspected Renal Salt Wasting Without Hyponatremia-
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
496
mi
from 43215
Mineola, NY
Fractional Urate Excretion in Nonedematous Hyponatremia
Study of Nonedematous Hyponatremia and the Utility of Fractional Urate Excretion in Hyponatremia and Suspected Renal Salt Wasting Without Hyponatremia-
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
496
mi
from 43215
Mineola, NY
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Open-Label Phase 3 Long-Term Safety Study of Migalastat
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials